{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:13:56Z","timestamp":1715386436008},"reference-count":26,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2023]]},"DOI":"10.3960\/jslrt.22038","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T22:11:21Z","timestamp":1679955081000},"page":"37-42","source":"Crossref","is-referenced-by-count":1,"title":["Benefit of prednisolone alone in nodal peripheral T-cell lymphoma with T follicular helper phenotype"],"prefix":"10.3960","volume":"63","author":[{"given":"Wataru","family":"Kitamura","sequence":"first","affiliation":[{"name":"Department of Hematology, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan,"},{"name":"Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Medical School, Okayama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Medical School, Okayama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Urata","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan,"},{"name":"Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Medical School, Okayama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Naoi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Medical School, Okayama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Kuyama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Rodr\u00edguez-Pinilla SM, Atienza L, Murillo C <i>et al.<\/i> Peripheral T-cell lymphoma with follicular T-cell markers. Am J Surg Pathol. 2008; 32: 1787-1799.","DOI":"10.1097\/PAS.0b013e31817f123e"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Dobay MP, Lemonnier F, Missiaglia E <i>et al.<\/i> Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. Haematologica. 2017; 102: e148-e151.","DOI":"10.3324\/haematol.2016.158428"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Watatani Y, Sato Y, Miyoshi H <i>et al.<\/i> Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia. 2019; 33: 2867-2883.","DOI":"10.1038\/s41375-019-0473-1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Swerdlow SH, Campo E, Pileri SA <i>et al.<\/i> The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127: 2375-2390.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Campo E, Jaffe ES, Cook JR <i>et al.<\/i> The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022; 140: 1229-1253.","DOI":"10.1182\/blood.2022015851"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36: 1720-1748.","DOI":"10.1038\/s41375-022-01620-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Advani RH, Skrypets T, Civallero M <i>et al.<\/i> Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. Blood. 2021; 138: 213-220.","DOI":"10.1182\/blood.2020010387"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Mihashi Y, Kimura S, Iwasaki H <i>et al.<\/i> Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell\/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers. Diagn Pathol. 2021; 16: 101.","DOI":"10.1186\/s13000-021-01163-7"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Lee YP, Yoon SE, Cho J <i>et al.<\/i> Comprehensive comparison of international prognostic indexes for follicular helper T-cell lymphoma. Ann Hematol. 2022; 101: 1535-1543.","DOI":"10.1007\/s00277-022-04805-y"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Siegert W, Agthe A, Griesser H <i>et al.<\/i> Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM\/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med. 1992; 117: 364-370.","DOI":"10.7326\/0003-4819-117-5-364"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Tucci A, Cerqui E, Ungari M <i>et al.<\/i> Continuous oral cyclophosphamide and prednisolone as a valuable treatment option for peripheral T cell lymphoma. Br J Haematol. 2011; 152: 113-116.","DOI":"10.1111\/j.1365-2141.2010.08367.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Ohmoto A, Fuji S. Cyclosporine for angioimmunoblastic T-cell lymphoma: a literature review. Expert Rev Hematol. 2019; 12: 975-981.","DOI":"10.1080\/17474086.2019.1652590"},{"key":"13","unstructured":"13 Tatetsu H, Imakane D, Nosaka K <i>et al.<\/i> [Follicular T-cell lymphoma successfully treated with long-term corticosteroid]. Rinsho Ketsueki. 2022; 63: 1497-1502 [in Japanese]."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Cheson BD, Fisher RI, Barrington SF <i>et al.<\/i> Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32: 3059-3068.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Manso R, Gonz\u00e1lez-Rinc\u00f3n J, Rodr\u00edguez-Justo M <i>et al.<\/i> Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features. Oncotarget. 2018; 9: 16124-16133.","DOI":"10.18632\/oncotarget.24592"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Sakata-Yanagimoto M, Enami T, Yoshida K <i>et al.<\/i> Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014; 46: 171-175.","DOI":"10.1038\/ng.2872"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Rodr\u00edguez M, Alonso-Alonso R, Tom\u00e1s-Roca L <i>et al.<\/i> Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers. Blood Adv. 2021; 5: 5588-5598.","DOI":"10.1182\/bloodadvances.2021005171"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Lemonnier F, Dupuis J, Sujobert P <i>et al.<\/i> Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood. 2018; 132: 2305-2309.","DOI":"10.1182\/blood-2018-04-840538"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Nguyen TB, Sakata-Yanagimoto M, Fujisawa M <i>et al.<\/i> Dasatinib is an effective treatment for angioimmunoblastic T-cell lymphoma. Cancer Res. 2020; 80: 1875-1884.","DOI":"10.1158\/0008-5472.CAN-19-2787"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Ghione P, Faruque P, Mehta-Shah N <i>et al.<\/i> T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma. Blood Adv. 2020; 4: 4640-4647.","DOI":"10.1182\/bloodadvances.2020002396"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity. 2014; 41: 529-542.","DOI":"10.1016\/j.immuni.2014.10.004"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Kurihara Y, Taoka K, Takagi E <i>et al.<\/i> Treatment of secondary immune thrombocytopenia with non-Hodgkin lymphoma: a case report and literature review. Intern Med. 2021; 60: 1583-1588.","DOI":"10.2169\/internalmedicine.5611-20"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Federico M, Rudiger T, Bellei M <i>et al.<\/i> Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 2013; 31: 240-246.","DOI":"10.1200\/JCO.2011.37.3647"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Crickx E, Poullot E, Moulis G <i>et al.<\/i> Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T\u2010cell lymphoma. Eur J Haematol. 2019; 103: 35-42.","DOI":"10.1111\/ejh.13239"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Dai L, He L, Wang Z <i>et al.<\/i> Altered circulating T follicular helper cells in patients with chronic immune thrombocytopenia. Exp Ther Med. 2018; 16: 2471-2477.","DOI":"10.3892\/etm.2018.6508"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Dunleavy K, Wilson WH. Angioimmunoblastic T-cell lymphoma: immune modulation as a therapeutic strategy. Leuk Lymphoma. 2007; 48: 449-451.","DOI":"10.1080\/10428190701245138"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/1\/63_22038\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T05:18:15Z","timestamp":1715318295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/1\/63_22038\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.22038","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"22038"}}